Robbins Arroyo LLP: Neurotrope, Inc. (NTRP) Misled Shareholders According to a Recently Filed Class Action

SAN DIEGO & NEW YORK--()--Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Neurotrope, Inc. (NasdaqCM: NTRP) in the U.S. District Court for the Southern District of New York. The complaint is brought on behalf of all purchasers of Neurotrope securities between January 7, 2016 and April 28, 2017, for alleged violations of the Securities Exchange Act of 1934 by Neurotrope's officers and directors. Neurotrope, a biopharmaceutical company, focuses on developing therapeutic and diagnostic technologies in the field of neurodegenerative diseases in the United States. The company’s product for treating Alzheimer's disease is known as Bryostatin-1 ("Bryostatin").

View this information on the law firm's Shareholder Rights Blog:
www.robbinsarroyo.com/shareholders-rights-blog/neurotrope-inc

Neurotrope Accused of Deceiving Shareholders About the Efficacy of Its Drug

According to the complaint, in a series of press releases, Neurotrope officials repeatedly misled investors regarding the efficacy of Bryostatin in clinical trials. During and after the trials were completed, Neurotrope represented that the drug could be "a potential breakthrough" in Alzheimer's treatment and that the company was "in a strong position to negotiate terms with pharmaceutical partners." On May 1, 2017, Neurotrope issued a press release announcing "positive top-line results" of their most recent study of Bryostatin that demonstrated improvement in patients with moderate to severe Alzheimer's. However, contrary to the positive statements in the press release, the data did not reveal any significant improvement in patients who took the 20 microgram dose. Further, Neurotrope completely omitted any data on patients who took the 40 microgram dose. On this news, Neurotrope's stock plummeted 63% from $18.81 per share on April 28, 2017, to a closing share price of $6.97 per share on May 1, 2017.

Neurotrope Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003
LKandinov@robbinsarroyo.com
www.robbinsarroyo.com

Release Summary

Do you own shares of Neurotrope, Inc.? Robbins Arroyo LLP is investigating claims on behalf of shareholders of Neurotrope.

$Cashtags

Contacts

Robbins Arroyo LLP
Leonid Kandinov
(619) 525-3990 or Toll Free (800) 350-6003
LKandinov@robbinsarroyo.com
www.robbinsarroyo.com